M
alaria transmission-blocking immunity is the concept that immunity can be induced in humans against the parasite stages that develop in the mosquito. The human immune factors could then function after a blood meal, against vulnerable gametes or later sporogonic stages, to inhibit development of the parasite in the mosquito (1) . Several laboratories are presently trying to develop a transmission-blocking vaccine for the human malaria parasite, Plasmodiumfakiparum (2) (3) (4) (5) (6) . A successful transmission-blocking component for a multisubunit vaccine, that would also target the malaria life cycle stages that develop in humans, is predicted to reduce the transmission of antigenic variants that arise naturally or as a result of drug or immune pressure (2, 7) . Reducing the geographic spread of drug or asexual vaccine-resistant variants in human populations would be a major contribution to malaria control. Although sterile immunity is unlikely, especially in areas of high transmission, a transmission-blocking vaccine would probably have a significant effect on the number of malaria infections in areas of low transmission, such as Sri Lanka (8) .
Within RBC, the malaria parasite multiplies asexually or differentiates sexually into male and female gametocytes. Gametocytes can continue developing only in a mosquito, where they emerge from the RBC and develop into extracellular gametes. Fertilization gives rise to zygotes which transform into motile ookinetes. These cross the gut wall and transform into oocysts. Sporozoites multiply within these structures, and after their release from mature, ruptured oocysts, can be inoculated into another individual to initiate a new infection. Any of these steps in sexual development represent potential targets for transmission intervention.
It has been shown for several species of Plasmodia, that antibodies induced by immunization or natural infection which are directed against gamete or zygote surface antigens, can indeed inhibit development of the malaria parasite when ingested with the blood meal (6, (9) (10) (11) (12) (13) . These antibodies are effective at three distinct points after gametogenesis: (a) fertilization of the macrogamete by the microgamete (14) ; (b) transformation of the ookinete into an oocyst (14) ; and (c) production of sporozoites within oocysts (15) . The P.faki~rum gamete surface antigens, Pfs230 and Pfs48/45, function as targets of antigamete antibodies, but display limited immunogenicity in humans (16, 17) . The early sexual stage antigen, Pfg27/25, is recognized by antibodies that can mediate transmission inhibition (5) . However the antigen is not surface exposed during sexual development, and the mechanism of this inhibition may be mediated by cross-reacting antigens. The most promising target is the zygote surface antigen, Pfs25 (3, 4) . Antibodies against this antigen inhibit both the development of the ookinete to an oocyst in the mosquito gut (14) and production of sporozoites (15) . The Pfs25 is conserved between parasites isolated worldwide (18) , and is highly immunogenic in experimental animals (3). However, a desirable feature of a third world vaccine is that a single inoculating dose should be effective and long-lasting, and the Pfs25 does not function as an immunogen in natural infections (19) . Therefore, reinfection will not provide a natural boost, and alternative methods of administration must be devised to generate'long-term protection from limited immunizations in the field.
We sought to identify novel sexual blood stage antigens that might render the parasite vulnerable to human antibodies and other immune factors in the mosquito blood meal, as these antigens might be expected to provide a boost upon parasite infection. Our goal was to produce mAbs that would recognize linear epitopes of gametocyte stage-specific antigens, that might be easily incorporated into a muhisubunit peptide vaccine. A possible transmission-blocking target was selected for functional studies, on the basis of its localization within the parasite.
This paper reports the generation of a mAb that recognizes a linear sequence of the P. falciparum 11.1 gene product (20) . The biochemical and immunological characterization of Pf11.1 has been obscured by its extensive cross-reactivity with other negatively charged P.fakiparum antigens, including Pf155/RESA, the megadalton asexual stage antigen Ag332, and a 260-kD asexual stage antigen (21) (22) (23) . Although the gene has been extensively studied, no specific protein product has been demonstrated. We show that the Pf11.1 gene product is a sexual blood stage antigen with an apparent monomer molecular mass of >2 megadaltons. The antigen, which we have named Pfs2400, appears in stage I gametocytes, accumulates during gametocyte maturation, and persists during emergence of the gametes, mAblA1 significantly blocks development of the sexual parasites into oocysts in the infected mosquito, and the localization of this antigen during sexual development suggests a site of action for the mAb in blocking sexual development.
Materials and Methods
Parasites. The P. falciparum gametocyte-producing NF54 isolate and its clonal derivative, 3D7 (24) , were cultured in human RBC and human serum from type A + donors, under conditions that promote gametocyte production (25) , and modified by the addition of 10 mM glucose to the culture medium. To obtain pure gametocytes, any surviving asexual trophozoites and schizonts were selectively killed between days 12 and 14 of culture, by suspension in 5% (wt/vol) D-sorbitol in distilled water for 5 min at room temperature (26) . Gametocytes and asexual rings were put back into culture for 2 d, after which, gametocytes were purified from asexual rings by Percoll gradient centrifugation (27) . The final gametocyte preparation contained <1% contamination with asexual blood stages. In vitro emergence of gametes was induced by incubation of garnetocytes in heat-inactivated PCS (14) , and macrogametes were harvested by Percoll gradient centrifugation as described (28) . Asexual parasites were obtained by maintaining the cultures at low parasitemias (<2%).
Immunizations. Purified gametocytes were pelleted at 37~
washed once in gametocyte retarding buffer (GRB; 1 170 mM NaC1, 10 mM glucose, 10 mM Tris, pH 7.4), and denatured by boiling in 3% SDS and 3 mM B-ME. (20) were synthesized. P3 is the three amino acid repeat peptide (EKD)6. P6 is the six amino acid repeat peptide (EEEKI.T)3. P9 is the degenerate nine amino acid repeat pep-
Immunolocalization of the Pfi2400 during Sexual Development. 3D7 parasites were cultured under conditions that promote sexual differentiation (25) . Under these conditions, the asexual parasitemia peaks at about day 5, and stage II gametocytes begin to appear in the culture at about day 7. Initial immunolocalization in developing sexual parasites, was performed by IFA on acetone-fixed blood smears (30) of these cultures and also of induced gametes, using mAblA1 at 10/zg/ml. The gametocyte stages were classified by visual inspection of phase-contrast images, according to the description of Carter and Miller (32) . Immunofluorescence of live gametes was performed after induction of gametogenesis, without further purification.
For immunoelectron microscopy, blood stage parasites and gametes were fixed and embedded in LR White resin (Polyscience, Warrington, PA) (33). Fixed P. fakiparum sporozoites (Gary Long strain) were embedded in LR Gold resin (Polyscience), containing 0.5% benzoin methyl ether as an initiator. Sections were incubated for 20 min in PBS containing 5% nonfat dry milk and 0.01% Tween 20. Grids were then incubated with mAblA1 in PBT (PBS containing 1% BSA and 0.01% Tween 20) for 2 h at room temperature. Control sections were incubated with normal mouse serum or PBT only. After washing in PBT, the grids were incubated for 1 h in 15 nm gold-labeled goat anti-mouse IgG (Janssen Pharmaceutical, Piscataway, NJ) diluted 1:20 in PBT, rinsed with PBT, fixed for 15 min in 2.5% glutaraldehyde, and then stained with 2% uranyl 1 Abbreviations used in this paper: GRB, gametocyte retarding buffer; IFA, indirect immunofluorescence; PBT, PBS containing 1% BSA and 0.01% Tween 20. acetate in 50% methanol and Reynold's lead citrate. Samples were examined under electron microscopes (model 100CX; JOEL Ltd., Tokyo, Japan; and model CEM 902; Zeiss, Oberkochen, Germany).
Western Blot Analysis. Gametocytes, macrogametes, asexually infected or control red blood cells were washed once in PBS at 37~ and extracted with 1% NP-40, in 150 mM NaC1, 50 mM Tris, pH 8.0 for 1-2 h on ice. Protease inhibitors were included in the extraction buffer as described (34) . NP-40 soluble extracts were boiled for 5 min in sample buffer (0.8% SDS, 1 M urea, 10 mM Tris, pH 8.0, 100 mM DTT), separated by SDS-PAGE, on a 3-10% polyacrylamide gradient gel prepared without a stacker, and transferred electrophoretically to nitrocellulose. Nitrocellulose strips were blocked with 3% BSA, 0.3% Tween 20 in 50 mM Tris, pH 7.4, 150 mM NaC1 (BSA/Tris-buffered saline containing 0.3% Tween 20 [TTBS]) for 1 h at room temperature, and incubated with 25 #g/ml mAb in BSA/TTBS for 1.5 h. After extensive washing in BSA/TTBS, blots were probed with lzSI-rabbit anti-mouse IgG (New England Nuclear, Boston, MA) diluted to 0.1 #Ci/ml in BSA/TTBS for 30 min, washed, dried, and autoradiographed.
Irarnunoprecipitation. NP-40 solubilized antigens were immunoprecipitated with mAblA1, and then adsorbed onto protein G agarose (Pierce Chemical Co., Rockford, IL) according to the manufacturer's protocol. The immunoprecipitated product was visualized by Western blot analysis.
Radioiraraunoassay. Polyvinylchloride microtiter plates were incubated overnight with 25 #g/ml of mAblA1 in PBS. mAblA1-coated plates were washed with PBS and blocked with 3% BSA/PBS. Plates were then incubated with NP-40 solubilized proteins at about 25 #g/ml in 0.5% NP-40, BSA/PBS, for 2 h at room temperature. Captured antigen was detected by counting, after binding of 12SI-labeled mAblA1. To assay for peptide inhibition of mAblA1 to the native antigen, labeled mAblA1 at about 1.5 x 10 s cpm/well (1.3 x 107 cpm/#g), was predetermined to produce a strong signal but not saturate the antigen binding sites. nSI-labeled mAblA1 was preincubated with peptides for 2 h at room temperature, before binding to parasite antigen trapped on plastic.
Transmission Inhibition Assays. Gametocytes of the P. fakiparurn strain NF54 were cultured in the Tipper system (35). 14 d after initiation of the culture, the parasitized red cell suspension (1.4 ml containing about 0.3 ml packed cells) of one tipper vessel was harvested and washed by centrifugation at 560 g for 2 rain in 3 ml KPMI 1640 onto a cushion of 0.5 ml KBC, prewarmed to 37~ 150 #1 of the parasitized cell preparation were added to a prewarmed cocktail consisting of 70 #1 of heat-inactivated human serum plus 40 #1 of flesh frozen type A+ human serum as a source of complement, and 10 #1 of mAb in PBS. Mixtures were distributed to prewarmed (37~ membrane feeders. Anopheles gambiae mosquitoes were allowed to feed for 10 rain, and fully fed mosquitoes were maintained at 26~ for 6 d. The midguts of 20 mosquitoes fed under each condition were examined for oocysts at this time, and the degree of transmission was calculated as the geometric mean of the number of oocysts. Transmission inhibition was assessed as the percent reduction in this number compared with the average oocyst numbers in control mosquitoes, fed in the absence of mAblA1. also demonstrated a fluorescence pattern consistent with a membrane or cytoskeletal association for the cognate antigen on acetone-fixed macrogametes. This antigen was chosen for further characterization, on the basis that it might be surface exposed and accessible to blocking antibodies in the mosquito blood meal.
Results

mAlx
Immunolocalization, IFA was used to establish the expression pattern of the epitope recognized by mAblA1, during sexual development of P. fakiparura. Immunofluorescence was positive for all sexual blood stage parasites (Fig. 1) . mAblA1 did not detect uninfected or asexuaLly infected RBC. The faint fluorescence associated with the small intraerythrocytic parasite, that looks like a late ring/early trophozoite by phaseconstrast ( Fig. 1 a) , is presumably a stage I gametocyte. The fluorescence intensity increased in the later gametocytes, from stage II onward, which are dearly distinguishable in the phasecontrast images. In these more mature gametocytes, the fluorescence pattern is consistent with an antigen localization surrounding the intraerythrocytic parasite. Thus, the antigen recognized by mAblA1 is produced very early after commitment of the parasites to sexual development, and accumulates during gametocyte maturation. The accessibility of the 1A1 epitope on the surface of live gametes was determined by IFA, as a preliminary evaluation of the possibility that this epitope might render the sexual parasite vulnerable to human antibodies in the mosquito blood meal. Gametocytes were induced to emerge from the infected RBC, and parasites were tested for reactivity with mAblAL As shown in Fig. 1 b, fluorescence was observed on the surface of some, but not all, of the live macrogametes. Intraerythrocytic gametocytes, visible in the same field by phasecontrast microscopy, were not detected by mAblA1. These data indicate that mAblA1 recognizes an epitope that is within the gametocyte-infected RBC, and is surface exposed during emergence of macrogametes. Its presence on only a subpopu- lation of macrogametes suggests that the antigen might be shed from the parasite surface, before fertilization.
Precise subceUular localization was determined by immunoelectron microscopy. As soon as sexual parasites could be distinguished morphologically from asexual trophozoites, gold label was observed. In immature gametocytes (Fig. 2 a) , label was observed throughout the erythrocyte cytoplasm. Some label was found adjacent to the parasitophorous vacuole membrane. A few gold particles were also found in the parasite cytoplasm, apparently associated with cytoplasmic vacuoles.
Mature gametocytes were ultrastructurally characterized by a pellicular complex consisting of three sets of membranes (36) . Immunoelectron microscopy showed that mAblA1 binds to an abundant antigen in the erythrocyte cytoplasm that is associated exclusively with the outer leaflet of the parasitophorous vacuole membrane (Fig. 2 b and inset) , consistent with the bright surface-like pattern observed by IFA. A few gold particles were seen in the gametocyte cytoplasm. No gold label was observed in asexual rings or schizonts (Fig. 2, c  and d) , and the epitope was also not detected in sporozoites (Fig. 2 e) .
The mAblA1 epitope was also localized in sexual parasites that had been induced to emerge from the infected erythrocyte. Fig. 3 a shows an activated gametocyte, with the gold label partitioning between the gamete plasmalemma and the RBC membrane, Some immunolabeling is scattered throughout the lysed erythrocyte cytoplasm, in association with remnants of erythrocyte cytoplasm and erythrocyte membrane. In this micrograph, the erythrocyte membrane has clearly lost its integrity, and appears to be pealing away from the emerging gamete. In extracellular gametes, the antigen is no longer detected (Fig. 3 b) .
Pfs2400. The molecular weight of the cognate antigen was determined by immunoprecipitation and Western blot analysis (Fig. 4) . MAblA1 detects a single parasite antigen that comigrates with the 2.4 megadahon subunit of the rabbit skeletal muscle protein, titin. The antigen is only present in protein extracts from gametocyte-infected RBCs and from emerging macrogametes. It can be detected by mAblA1 under both reducing (Fig. 4) and nonreducing conditions (data not shown), indicating that the functional epitope is not dependent upon tertiary conformation or the presence of disulfide bonds. No reactivity was detected in protein extracted from RBCs infected with asexual stages or from uninfected RBCs. In keeping with the nomenclature for newly identified P. Jalciparum sexual stage antigens of unknown function, we refer to the antigen as Pfs2400 for sexual stage-specific antigen with an apparent Mr of 2400.
As many plasmodial antigens contain tandemly repeated amino acid sequences, which are frequently immunodominant, a RIA was performed to address the nature of the epitope recognized by mAblA1 (Fig. 5) . mAblA1 was immobilized in plastic wells of microtiter plates, and used to capture native Pfs2400 from P. fakiparum gametocyte protein extracts or control proteins. Probing with tracer amounts of 12sI-labeled mAblA1 resulted in a strong signal when gametocyte proteins were the source of antigen, consistent with the possibility that the epitope might be present in multiple copies on the antigen. No Pfs2400 was detected in asexual stage proteins, BSA, or gametocyte culture supernatant.
To test directly for the release of Pfs2400 from extracellular gametes, gametocytes were induced to emerge, and both the supernatant and the macrogamete protein extract were assayed for the presence of the antigen by RIA. As seen in Fig. 5 , Pfs2400 can be detected in both the supernatant and the cell extract, providing biochemical confirmation of our structural data that the antigen is shed from the parasite during emergence. No signal was detected in control FCS.
Pfs2400
Is the Product of the Pfll.1 Gene. To determine the identity of the antigen and the fine specificity of the epitope recognized by mAblA1, we tested the possibility that the Pfs2400 is the product of the P. falciparum 11.1 gene, a recently characterized megadahon antigen distributed in small clusters surrounding parasitophorous vacuole membrane in mature gametocytes (37) . mAblA1 binding to native Pfs2400 was assayed in the presence and absence of synthetic peptides In control experiments, mAb 7H11.E8, against the circumsporozoite protein from P. brasilianum, showed no reactivity with any P. fakiFarum or RBC protein.
corresponding to each of the three blocks of tandem repeat sequences encoded by the Pill.1 gene. As shown in Fig. 6 , P9, consisting of two copies of the Pf11.1 degenerate nine amino acid repeat sequence, inhibited mAblA1 binding to Pfs2400 in a dose-dependent manner. Complete inhibition was achieved at 50 #g/ml. The other two peptides, P3 and P6, corresponding to the three and six amino acid repeat se- ~ansmission Inhibition. As the surface of live macrogametes is accessible to binding by mAblA1, at least during emergence from the RBC, we sought to determine the ability of mAblA1 to block sexual development of the parasite in P. fakiparum gametocyte-fed mosquitoes. Table 1 shows that, in three separate experiments, this reagent reduced the formation of oocysts within the mosquito midgut, compared with mosquitoes fed on control human serum. In two experiments, mAblA1 reduced the mean number of oocysts formed by 70 and 80% at a final concentration of only 92.6 pg/ml. At lower concentrations (Expt. 3), mAblA1 still reduced oocyst formation. Even at 1 ~g/ml, oocyst numbers were reduced by 41%, compared with human control serum. In this experiment, an unrelated mouse mAb bearing the same IgG1 isotype as mAblA1, had little effect on sexual development at 74/~g/ml.
Discussion
We have identified a linear epitope on the Pfll.1 gene product, that can mediate a substantial transmission blockade in an antibody-dependent fashion. The parasite load in these mosquito-feeding experiments is much higher than what is generally found in the field, where most mosquitoes are naturally infected with only one or a few oocysts (38) . Mosquito feeding in the presence of a reduced number of gametocytes, will assess whether a 70-80% reduction in oocysts might represent real protection. MAblA1, generated during this investigation, is specific for Pf11.1, a large sexual stage-specific antigen, containing at least three blocks of tandemly repeated amino acid sequences (20, 37) . Using peptides corresponding to tandem copies of each of the known repeats, the fine specificity of mAblA1 was shown to be directed against the nine amino acid repeat block. The Pf11.1 locus is subject to DNA breakage and telomere healing, with concomitant loss of gene expression in laboratory isolates (37) . Although the truncated Pf11.1 gene was observed in a laboratory clone that can initiate sexual development and generate gametocytes in culture, there was no evidence of the truncated gene in parasite DNA isolated directly from 15 patients (37), suggesting that Pf11.1 expression is necessary for some later step in sporogonic development, in vivo.
We suggest that mAblA1 probably inhibits the formation of extracellular gametes, because the conserved but degenerate Pf11.1 nonapeptide repeats are briefly exposed on live sexual parasites during emergence of gametes from activated gametocytes. Perhaps mAblA1 interferes with the complete shedding of the RBC and parasitophorous vacuole membranes.
Low concentrations (ml0/zg/ml) of transmission-blocking mAb directed against Plasmodium vivax gamete surface antigens have been shown to increase the number of oocysts generated in mosquitoes fed on mature P. vivax gametocytes, perhaps by cross-linking male and female gametes to facilitate fertilization (11, 39) . Transmission enhancement has not yet been observed in P.. fakiparum, and indeed, the presence of even lower concentrations (I #g/ml) of mAblA1 does not increase oocyst numbers in P. fakiparum-infected mosquito.
The data presented here indicate that mAblA1 is probably functioning before gamete fertilization, unless the soluble Pf11.1 antigen has a role in sexual development in the mosquito midgut. Since low mAblA1 concentrations in the blood meal still produce a dramatic reduction in the number of oocysts that develop in the infected mosquito, we will test the possibility that the antibody may be agglutinating activated gametocytes, and also assay the contribution of complement to the observed protection. Western blot analysis of both reduced and unreduced bloodstage parasite extracts, with mAblA1, demonstrated that the Pfll.1 gene product is about 2.4 megadaltons in both gametocytes and emerging gametes. The antigen does not appear to be processed while it is still associated with the activated sexual parasite, mAblE10, the mAb reported to identify the Pf11.1 gene product, also recognizes a linear epitope contained within the nine amino acid repeat (37) . However, mAblE10 detects a smear from gametocyte protein extracts, that extends from the top to the 50-kD region of a gradient gel (37) . It is possible that mAblE10 cross-reacts with other negatively charged gametocyte stage antigens. This is supported by the finding that the detailed localization of the mAblE10 epitope is slightly different from the even distribution of gold label around the parasitophorous vacuole membrane observed with mAblA1. Alternatively, as the authors proposed, degraded antigen is responsible for the dramatic smear on Western blot analysis with mAblE10 (37) .
The Pf11.1 antigen has several features that make it an attractive candidate for a malaria transmission-blocking vaccine. The genomic sequence encoding the nine amino acid repeats is degenerate, but present in at least 20 isolates from eight geographically distinct locations (40, 20) , and the encoded repeats can act as a target for mAblAl-mediated inhibition of sporogonic development. In addition, antibodies against the nine amino acid repeats have been reported to be present in human immune sera (41, 42) , indicating that Pf11.1 or one of the glutamate-rich, cross-reacting P.falcilmrum antigens is immunogenic in a human infection. This suggests that it should be possible to identify a peptide containing a minimum epitope based on this sequence, which is immunogenic in humans. Further, since the antigen is expressed in blood stage parasites very early after sexual differentiation, reinfection might be expected to boost the antibody titers to transmission-blocking levels during the 12-14 d gametocyte maturation time, after a primary immunization with Pfll.1-derived epitopes. Whereas the Pf11.1 six amino acid repeat block is absent in some P.fakiparum isolates, the three amino acid repeats are also conserved (20) , and therefore represent a second potential transmission-blocking target. Experiments are in progress to test the capacity of peptides corresponding to these repeats to elicit polyclonal antibodies that, alone or in combination, can mediate a complete transmission blockade.
